The current cost-effective study has shown that earlier therapy starting with normal ALT values and a high viral value may be cost-efficacious compared to delaying the therapy until the occurrence of the active hepatitis stage in adult subjects with CHB [83], demonstrating the highly capable long-term effectiveness and safety of a recent anti-HBV study that posed a high genetic barrier to resistance and reducing the cost [84,85,86]. The gene discussed is GPT; the disease is hepatitis A virus infection.